Why publish your research with Antibody Therapeutics?

Antibody Therapeutics and a peer-reviewed, fully open access journal that provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community. Key topics of the Journal include: 

• Target and antibody discovery
• Mechanistic research
• New technology and methods
• Manufacturing
• Clinical trials
• Regulation
• Policies
• And more

Antibody Therapeutics is pleased to offer a 50% discount on article processing charges until 30 June 2025. Click here to find out more.

The Journal is proud to present that the following reasons make our journal the perfect home for your research.

• Important topic in biomedicine
• Fully open access
• Indexed in PubMed, Scopus, DOAJ, ESCI, and CiteScore
• Global readership
• Rapid decision time
• Rigorous peer review
• Official journal of the Chinese Antibody Society
• Published in partnership with Oxford University Press
• Member discounts on APCs
• Ethical and trustworthy research

Important topic in biomedicine

A journal dedicated solely to antibody therapeutic research holds significant importance due to its ability to offer targeted, effective, and personalized treatment research for a range of diseases, with the potential to revolutionize the field of medicine, leading to improved patient outcomes. The versatility and potential for innovation in the field of antibody therapeutics make the studies conducted a vital component of modern therapeutic interventions.

Fully open access

Antibody Therapeutics prides itself in being a fully open access (OA) journal. Publishing OA offers several benefits for authors including: 

• Increased visibility and accessibility: OA articles are freely available to anyone, removing any barriers to knowledge. This leads to increased readership and usage by a global audience, including researchers, students, policymakers, and the general public. 
• Higher citation potential: OA articles tends to receive higher citation rates compared to articles published behind paywalls. This further boosts the impact and recognition of your work. 
• Public engagement and societal impact: As mentioned above, publishing OA allows research to reach a broader audience beyond academic. This enables the ability for your research to have a potential impact on societal needs. 
• Compliance with funding agency policies: Many funding agencies and institutions now require research outputs to be published OA, as it aligns with the principles of public funding and maximizing societal and science progress. 

Oxford University Press has Read and Publish agreements with institutions and consortia which provide funding for open access publication. This means authors from participating institutions can publish open access, and the institution will pay the charge. Click here to see if your institution is participating.

Indexed in PubMed, Scopus, DOAJ, ESCI, and CiteScore

The Journal is proudly indexed in the following:

• PubMed: a widely used and highly regarded biomedical literature database. Antibody Therapeutics is proudly indexed in PubMed which means your published work with the journal can benefit from increased discoverability, credibility and prestige, and enhanced research impact.
• Scopus: which provides a gateway to a global audience, accessible to researchers, scholars, and practitioners worldwide. Additionally, Scopus is known for its rigorous evaluation process. Journals indexed in Scopus undergo annual re-evaluation to maintain high content quality. The journal has a 2023 CiteScore of 8.7
• DOAJ: (Directory of Open Access Journals) indexes and promotes quality peer-reviewed open access journals from around the world. DOAJ upholds the reputation for advocating best practices and standards in open access journal. Antibody Therapeutics is proud to be indexed in DOAJ, showcasing our respectability and prominence.
• ESCI: Antibody Therapeutics has been accepted by Clarivate for indexing in the Emerging Sources Citation Index (ESCI). This means that all content published in the Journal will now be indexed in Web of Science. Journals indexed in the ESCI are eligible for an Impact Factor, so we hope that the journal will receive its first Impact Factor soon.

Global readership

Antibody Therapeutics boasts a wide distribution of readers demonstrating that the research published in the journal truly has a global impact, with readers from Asia comprising roughly 25%, readers from Europe comprising 19%, and readers from North American comprising 42%. 

Rapid decision time

Antibody Therapeutics strives for rapid peer review. The journal averages 29 days from submission to first decision. 

Rigorous and constructive peer review

Antibody Therapeutics conducts rigorous and constructive single-anonymized peer review, meaning that the identity of the authors is known to the editors and to the reviewers, but that the reviewers’ identities are known only to the editors and are hidden from the authors. 

All submissions to the Journal are initially reviewed by one of the Editors. Manuscripts that pass initial review are sent out for peer review to at least two independent reviewers. Based on the feedback from these reviewers and the Editors' judgment a decision is given on the manuscript. 

If a paper is not acceptable in its present form, the Journal shares suggestions for revisions to the author

Official journal of the Chinese Antibody Society

The Chinese Antibody Society (CAS) is a nonprofit professional organization focusing on therapeutic antibodies and relevant therapeutic modalities. The society aims to bring together industry leaders, healthcare providers, researchers, academics, and investors to connect and collaborate on the discovery, development, manufacturing, and marketing of therapeutic antibodies.  Through its programs and services, the CAS serves as a platform fostering communication and collaboration among its members worldwide, in particular those in China and U.S. It also functions as a bridge to accelerate the approval by international regulatory agencies and marketing of antibody-based therapeutics developed in China. 

Published in partnership with Oxford University Press

As a department of the University of Oxford, OUP is a mission-driven, non-profit publisher committed to delivering world-class academic and educational resources and making them available as widely as possible. OUP understands the importance of making research accessible so that not only researchers, but also practitioners and policymakers around the world, are well-equipped with the latest information to better serve their communities.  

Member discounts on APCs

For a limited time through 30 June 2025, all submitting authors are eligible to receive a 50% APC discount. Corresponding authors who are members of the Chinese Antibody Society are eligible for this discount as well as new authors. For more information, please refer to the author guidelines here.

Ethical and trustworthy research

Antibody Therapeutics follows Committee on Publication Ethics (COPE) guidelines on ethical oversight. We take research integrity seriously, and all research published in the journal must have been conducted in a fair, trustworthy, and ethical manner.  

Ready to submit?

Please refer to our instructions to authors for more detailed information and manuscript requirements and our submission site if you are ready to submit. If you have any questions, please email the Editorial Office at [email protected].